8-K: Pacira Reports Strong Q4, Full-Year 2025 Results

Pacira BioSciences, Inc. announced record-high EXPAREL sales and strong full-year 2025 financial results, driven by its 5x30 strategy and strategic partnerships.

Summary

• Fourth quarter 2025 revenues were $196.9 million, a 5% increase over Q4 2024.
• Full-year 2025 revenues reached $726.4 million, a 4% increase over 2024.
• EXPAREL net product sales hit a record high, growing 7% in Q4 2025 to $155.8 million and 5% for the full year to $575.1 million.
• Full-year GAAP net income was $7.0 million ($0.16 per share) in 2025, a significant improvement from a GAAP net loss of $99.6 million ($2.15 per share) in 2024.
• Adjusted EBITDA for full-year 2025 was $186.5 million, down from $223.9 million in 2024.
• The company repurchased 5.9 million shares of common stock for $150.0 million in 2025, with $150.0 million remaining on the authorization expiring December 31, 2026.
• Pacira ended Q4 2025 with $238.4 million in cash, cash equivalents, and available-for-sale investments.
• The 5x30 strategy contributed to over 2.5 million patients benefiting from products and achieving the highest gross margins in company history.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, primarily driven by strong EXPAREL sales growth, a return to GAAP profitability, and strategic moves to expand market reach and intellectual property protection, despite some increases in operating expenses.

Positives

• Record-high EXPAREL sales driven by 7% volume growth in Q4 2025, marking the strongest Q4 performance in three years.
• Full-year 2025 revenues increased by 4% to $726.4 million.
• Significant improvement in GAAP net income, from a $99.6 million loss in 2024 to a $7.0 million income in 2025.
• Achieved the highest gross margins in the company's history in 2025.
• Strengthened intellectual property for EXPAREL, providing protection into the 2040s.
• Enhanced Board of Directors with the appointment of Samit Hirawat, M.D., bringing extensive clinical development and industry expertise.
• Strategic partnership with LG Chem to expand EXPAREL access in select Asian-Pacific markets, including an upfront payment and future royalties.
• Share repurchase program actively utilized, repurchasing $150.0 million worth of shares in 2025.
• Total operating expenses decreased from $774.3 million in 2024 to $707.2 million in 2025, primarily due to the absence of the 2024 goodwill impairment.

Negatives

• Fourth quarter GAAP net income decreased significantly to $1.6 million ($0.04 per share) in Q4 2025 from $16.0 million ($0.35 per share) in Q4 2024.
• Full-year adjusted EBITDA decreased to $186.5 million in 2025 from $223.9 million in 2024.
• Fourth quarter adjusted EBITDA decreased to $38.7 million in Q4 2025 from $62.5 million in Q4 2024.
• Total operating expenses in Q4 2025 increased to $194.5 million from $162.5 million in Q4 2024, driven by higher R&D and SG&A expenses.
• R&D expenses increased to $37.5 million in Q4 2025 from $23.9 million in Q4 2024, partly due to a $5.0 million upfront payment for PCRX-2002 in-licensing.
• SG&A expenses increased to $101.6 million in Q4 2025 from $79.6 million in Q4 2024, impacted by unanticipated costs associated with business development due diligence and litigation.
• ZILRETTA net product sales decreased slightly by 1% for the full year 2025 to $116.6 million.
• Cash and cash equivalents decreased from $276.774 million at December 31, 2024, to $158.545 million at December 31, 2025.
• Short-term available-for-sale investments decreased from $207.841 million at December 31, 2024, to $79.879 million at December 31, 2025.

Risks

• Risks associated with acquisitions, such as the risk that the acquired businesses and/or assets will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the transaction will not occur.
• Risks related to manufacturing and supply chain.
• Impact of global and United States economic conditions (including tariffs, inflation and rising interest rates) on business, including revenues, financial condition, cash flows and results of operations.
• Uncertainty regarding the success of sales and manufacturing efforts in support of the commercialization of EXPAREL, ZILRETTA and iovera.
• Uncertainty regarding the rate and degree of market acceptance of EXPAREL, ZILRETTA and iovera.
• Risks related to the size and growth of the potential markets for EXPAREL, ZILRETTA and iovera and the ability to serve those markets.
• Risks associated with plans to expand the use of EXPAREL, ZILRETTA and iovera to additional indications and opportunities, and the timing and success of any related clinical trials for EXPAREL, ZILRETTA, iovera and any other product candidates, including but not limited to PCRX-201.
• Uncertainty regarding the commercial success of EXPAREL, ZILRETTA and iovera.
• Risks related to the timing and success of United States Food and Drug Administration supplemental New Drug Applications and premarket notification 510(k)s.
• Risks related to the timing and success of European Medicines Agency Marketing Authorization Applications.
• Risks associated with plans to evaluate, develop and pursue additional product candidates utilizing proprietary multivesicular liposome (pMVL) drug delivery technology or proprietary high-capacity adenovirus (HCAd) vector platform.
• Uncertainty regarding the approval of the commercialization of products in other jurisdictions (by either the company or its partners).
• Risks related to the ability to successfully complete capital projects.
• The outcome of any litigation.
• The recoverability of deferred tax assets.
• Assumptions associated with contingent consideration payments.
• Assumptions used for estimated future cash flows associated with determining the fair value of the company.
• The anticipated funding or benefits of the share repurchase program.

Future Outlook

Pacira BioSciences provided full-year 2026 financial guidance, projecting EXPAREL net product sales of $600 million to $620 million and total revenues of $745 million to $770 million. The company anticipates non-GAAP gross margin between 77% and 79%, non-GAAP R&D expense of $105 million to $115 million, and non-GAAP SG&A expense of $320 million to $340 million.

Management Comments

• "2025 was a year of disciplined execution for Pacira. With the launch of our 5x30 strategy, we reignited momentum across the business and delivered strong, measurable progress." Frank D. Lee, CEO.
• "Our products benefitted more than 2.5 million patients, generated $726 million in revenue, and achieved the highest gross margins in our company's history. Together, these results clearly validate the impact and promise of our 5x30 strategy." Frank D. Lee, CEO.
• "Our performance continues to be led by EXPAREL, which is benefitting from expanding reimbursement, growing commercial adoption, and strengthened intellectual property providing protection into the 2040s." Frank D. Lee, CEO.
• "We further extended our commercial reach through strategic collaborations, while advancing clinical programs positioned to deliver a data-rich year. Pacira enters 2026 stronger than ever as we continue to redefine what is possible in innovative non-opioid pain management." Frank D. Lee, CEO.

Industry Context

StockSavvy.ai notes that Pacira's focus on non-opioid pain therapies aligns with a broader industry trend towards reducing opioid dependence, driven by public health concerns and regulatory pressures. The expansion of EXPAREL's intellectual property into the 2040s provides a significant competitive moat in a market increasingly scrutinized for patent cliffs. The strategic partnership with LG Chem for Asian-Pacific markets indicates a move towards global market penetration, a common growth strategy for mature pharmaceutical products, especially as domestic growth rates may stabilize.

Comparison to Industry Standards

• Pacira's 2025 full-year revenue growth of 4% to $726.4 million, while positive, is moderate compared to some high-growth biotech firms, but solid for a company with established commercial products like EXPAREL. For instance, companies like Regeneron Pharmaceuticals (REGN) or Vertex Pharmaceuticals (VRTX) often report higher revenue growth rates driven by newer blockbuster drugs, though they operate in different therapeutic areas.
• The GAAP net income turnaround from a $99.6 million loss in 2024 to a $7.0 million income in 2025 is a strong recovery, especially considering the prior year's goodwill impairment. This indicates improved operational efficiency or reduced one-time charges.
• EXPAREL's 7% volume growth in Q4 2025 and strengthened IP protection into the 2040s positions it favorably against competitors in the pain management space, where patent expirations can severely impact revenue. For example, generic competition has historically impacted drugs like Lyrica (pregabalin) from Pfizer, highlighting the importance of strong IP.
• The adjusted EBITDA decline from $223.9 million in 2024 to $186.5 million in 2025, despite revenue growth, suggests increased operating expenses, particularly in R&D and SG&A, which warrants closer scrutiny. This contrasts with companies that maintain or improve EBITDA margins alongside revenue growth, indicating potential investments or cost pressures.

Management Changes

Corporate Governance

Legal Proceedings

• Settlement of patent infringement lawsuits against Fresenius Kabi USA, LLC, eVenus Pharmaceuticals Laboratories, Inc., and Jiangsu Hengrui Pharmaceuticals Co., Ltd., resulting in $7.0 million legal settlement costs in 2025.
• Receipt of a $23.1 million cash payment from a U.S. District Court judgment requiring Research Development Foundation to repay previously paid royalties on EXPAREL sales, plus an additional $5.2 million in statutory interest.

Stakeholder Impact

• Shareholders: Benefit from share repurchase program ($150.0 million in 2025), improved GAAP net income, and positive revenue growth. Potential for future growth through strategic partnerships and pipeline advancement.
• Patients: Benefit from expanded access to non-opioid pain therapies (EXPAREL, ZILRETTA, iovera), with over 2.5 million patients benefiting in 2025.
• Employees: Impacted by workforce reduction related to the decommissioning of the 45-liter EXPAREL manufacturing suite in July 2025.
• Partners (LG Chem): New strategic partnership to commercialize EXPAREL in Asian-Pacific markets, creating new revenue streams and market opportunities.
• Creditors: Repayment of 0.75% convertible senior notes due 2025 in cash on August 1, 2025.

Next Steps

• LG Chem plans to file for marketing authorizations for EXPAREL in South Korea and Thailand in 2026.
• Pacira management team will host a conference call on February 26, 2026, at 4:30 p.m. ET to discuss financial results and recent developments.
• Continue advancing clinical programs, including PCRX-201 in Phase 2 clinical development for OA of the knee.
• Continue to execute on the 5x30 strategy.

Key Dates

Recommendation

The company demonstrated solid revenue growth, particularly with EXPAREL, and a return to GAAP profitability, which are positive indicators. Strategic moves like the LG Chem partnership and strengthened IP are also favorable. However, the decline in adjusted EBITDA and the increase in operating expenses, especially SG&A due to unanticipated costs, warrant caution. While the outlook for 2026 is positive, these factors suggest a 'hold' recommendation as investors should monitor the company's ability to manage costs and translate revenue growth into improved profitability and cash flow in the coming quarters.

Keywords

Pacira BioSciences, PCRX, EXPAREL, ZILRETTA, iovera, Non-opioid pain management, Financial results, Q4 2025, Full-year 2025, Biopharmaceuticals, Pain therapy, Pharmaceuticals, Clinical development, Corporate governance, Share repurchase, Strategic partnership, LG Chem, Samit Hirawat